JP2018519810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519810A5 JP2018519810A5 JP2017562681A JP2017562681A JP2018519810A5 JP 2018519810 A5 JP2018519810 A5 JP 2018519810A5 JP 2017562681 A JP2017562681 A JP 2017562681A JP 2017562681 A JP2017562681 A JP 2017562681A JP 2018519810 A5 JP2018519810 A5 JP 2018519810A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 214
- 239000003814 drug Substances 0.000 claims 39
- 102000013498 tau Proteins Human genes 0.000 claims 23
- 108010026424 tau Proteins Proteins 0.000 claims 23
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 8
- 102000057063 human MAPT Human genes 0.000 claims 8
- 208000000044 Amnesia Diseases 0.000 claims 7
- 208000026139 Memory disease Diseases 0.000 claims 7
- 230000001149 cognitive effect Effects 0.000 claims 7
- 230000006984 memory degeneration Effects 0.000 claims 7
- 208000023060 memory loss Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000016784 immunoglobulin production Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 229940125759 BACE1 protease inhibitor Drugs 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 101100029763 Rattus norvegicus Inpp5j gene Proteins 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020186282A JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171693P | 2015-06-05 | 2015-06-05 | |
| US62/171,693 | 2015-06-05 | ||
| PCT/US2016/035409 WO2016196726A1 (en) | 2015-06-05 | 2016-06-02 | Anti-tau antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186282A Division JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519810A JP2018519810A (ja) | 2018-07-26 |
| JP2018519810A5 true JP2018519810A5 (https=) | 2019-11-28 |
| JP6793134B2 JP6793134B2 (ja) | 2020-12-02 |
Family
ID=56118083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562681A Active JP6793134B2 (ja) | 2015-06-05 | 2016-06-02 | 抗ｔａｕ抗体及び使用方法 |
| JP2020186282A Active JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
| JP2023133420A Active JP7835706B2 (ja) | 2015-06-05 | 2023-08-18 | 抗ｔａｕ抗体及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186282A Active JP7403429B2 (ja) | 2015-06-05 | 2020-11-09 | 抗ｔａｕ抗体及び使用方法 |
| JP2023133420A Active JP7835706B2 (ja) | 2015-06-05 | 2023-08-18 | 抗ｔａｕ抗体及び使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10112990B2 (https=) |
| EP (2) | EP4465050A3 (https=) |
| JP (3) | JP6793134B2 (https=) |
| KR (1) | KR102768863B1 (https=) |
| CN (2) | CN114057872A (https=) |
| AR (1) | AR104875A1 (https=) |
| AU (2) | AU2016270858B2 (https=) |
| CA (2) | CA2986942C (https=) |
| CL (2) | CL2017003063A1 (https=) |
| CO (1) | CO2018000046A2 (https=) |
| CR (1) | CR20180013A (https=) |
| DK (1) | DK3303386T3 (https=) |
| ES (1) | ES2991587T3 (https=) |
| FI (1) | FI3303386T3 (https=) |
| IL (3) | IL314569A (https=) |
| MA (1) | MA44955A (https=) |
| MX (3) | MX392257B (https=) |
| NZ (2) | NZ775762A (https=) |
| PE (1) | PE20180317A1 (https=) |
| PH (2) | PH12021551770A1 (https=) |
| PL (1) | PL3303386T3 (https=) |
| PT (1) | PT3303386T (https=) |
| RU (1) | RU2732122C2 (https=) |
| SG (1) | SG10201911349YA (https=) |
| SI (1) | SI3303386T1 (https=) |
| TW (4) | TWI790642B (https=) |
| UA (1) | UA126272C2 (https=) |
| WO (1) | WO2016196726A1 (https=) |
| ZA (3) | ZA201707644B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| EA201792184A1 (ru) | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| EP4465050A3 (en) | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3496750A2 (en) * | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| MA48595A (fr) | 2016-12-07 | 2020-03-18 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
| CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| BR112019017021A2 (pt) * | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| KR20190133162A (ko) * | 2017-03-28 | 2019-12-02 | 제넨테크, 인크. | 신경퇴행성 질병의 치료 방법 |
| CN110881274B (zh) * | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| JP2020530554A (ja) | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| EP3697814A1 (en) | 2017-10-16 | 2020-08-26 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| KR102710762B1 (ko) | 2017-10-25 | 2024-09-25 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| MA53338A (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica Nv | Dosages pour détecter la neurodégénérescence |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| CA3089649A1 (en) * | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-tip-1 antibodies and uses thereof |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| WO2020154150A1 (en) * | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| CA3127450A1 (en) * | 2019-01-22 | 2020-07-30 | Clemson University Research Foundation | Anti-elastin antibodies and methods of use |
| BR112021014420A2 (pt) * | 2019-01-28 | 2021-09-21 | Tuojie Biotech (Shanghai) Co., Ltd. | Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo |
| AU2020219804A1 (en) | 2019-02-08 | 2021-08-19 | Ac Immune S.A. | Method of safe administration of phosphorylated Tau peptide vaccine |
| WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EA202192891A1 (ru) * | 2019-04-24 | 2022-02-04 | Янссен Фармасьютикалз, Инк. | Гетерологичное введение анти-тау вакцин |
| CN114174515A (zh) * | 2019-05-27 | 2022-03-11 | 英属哥伦比亚大学 | tau中的构象特异性表位、其抗体和其相关方法 |
| JP7227895B2 (ja) * | 2019-12-23 | 2023-02-22 | 株式会社堀場製作所 | 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット |
| US20230391855A1 (en) * | 2020-10-21 | 2023-12-07 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| CN113005096B (zh) * | 2021-01-19 | 2022-10-14 | 华中科技大学 | 分泌抗丝氨酸磷酸化tau蛋白单克隆抗体的杂交瘤细胞株 |
| IL310382A (en) * | 2021-08-27 | 2024-03-01 | Genentech Inc | Methods for treating tau pathologies |
| KR102888596B1 (ko) * | 2021-09-09 | 2025-11-20 | 알즈패스, 인크. | 포스포-타우 항체 및 사용 방법 |
| WO2023135200A1 (en) * | 2022-01-12 | 2023-07-20 | Gtinvent Limited | Method for detecting a tau protein in a saliva sample |
| US20250355002A1 (en) * | 2022-06-14 | 2025-11-20 | The Johns Hopkins University | Identification of tdp-43 cryptic exon-encoded neoepitopes as functional fluid biomarkers for alzheimer's disease and related dementia |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | TAU PROTEIN BINDING COMPOUNDS |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU7121191A (en) * | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP1585520A1 (en) | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| SG10201912639SA (en) * | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| ES2548686T3 (es) | 2010-10-07 | 2015-10-20 | Ac Immune S.A. | Anticuerpos que reconocen fosfo-Tau |
| BR112013008765B8 (pt) | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| WO2012083370A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| ES2656442T3 (es) | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| RU2639537C2 (ru) | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
| US9371376B2 (en) | 2011-12-20 | 2016-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
| JP6293731B2 (ja) * | 2012-04-05 | 2018-03-14 | エーシー イミューン エス．エー． | ヒト化タウ抗体 |
| HK1209768A1 (en) | 2012-07-03 | 2016-04-08 | Washington University | Antibodies to tau |
| PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
| CA2885924C (en) | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| WO2014059442A2 (en) * | 2012-10-12 | 2014-04-17 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| PT2935326T (pt) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
| US9039633B2 (en) | 2012-12-24 | 2015-05-26 | Transmed7, Llc | Automated, selectable, soft tissue excision biopsy devices and methods |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CN105143258B (zh) * | 2013-03-15 | 2020-06-23 | Ac免疫有限公司 | 抗Tau抗体和使用方法 |
| ES2800827T3 (es) * | 2013-06-10 | 2021-01-04 | Ipierian Inc | Procedimientos de tratamiento de una tauopatía |
| EP3074420A2 (en) | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
| HRP20200384T1 (hr) | 2013-12-20 | 2020-06-12 | F. Hoffmann - La Roche Ag | Humanizirana anti-tau(ps422) protutijela i načini uporabe |
| WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| EP3204411A4 (en) | 2014-10-10 | 2018-03-28 | National Research Council of Canada | Anti-tau antibody and uses thereof |
| US10323082B2 (en) | 2014-10-14 | 2019-06-18 | The Research Foundation For Mental Hygiene, Inc. | Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US10202444B2 (en) | 2015-02-24 | 2019-02-12 | Rpeptide, Llc | Anti-tau antibodies |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| EP4465050A3 (en) | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| WO2016201434A2 (en) | 2015-06-12 | 2016-12-15 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| KR102770650B1 (ko) | 2015-07-06 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | 타우 결합 항체 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| EP3448875A4 (en) | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| PL3484916T3 (pl) | 2016-07-12 | 2021-07-19 | H. Lundbeck A/S | Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania |
| CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| MA48595A (fr) | 2016-12-07 | 2020-03-18 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
| KR20190133162A (ko) | 2017-03-28 | 2019-12-02 | 제넨테크, 인크. | 신경퇴행성 질병의 치료 방법 |
-
2016
- 2016-06-02 EP EP24192932.2A patent/EP4465050A3/en active Pending
- 2016-06-02 EP EP16728559.2A patent/EP3303386B1/en active Active
- 2016-06-02 ES ES16728559T patent/ES2991587T3/es active Active
- 2016-06-02 NZ NZ775762A patent/NZ775762A/en unknown
- 2016-06-02 KR KR1020177037588A patent/KR102768863B1/ko active Active
- 2016-06-02 CR CR20180013A patent/CR20180013A/es unknown
- 2016-06-02 WO PCT/US2016/035409 patent/WO2016196726A1/en not_active Ceased
- 2016-06-02 RU RU2017145540A patent/RU2732122C2/ru active
- 2016-06-02 PT PT167285592T patent/PT3303386T/pt unknown
- 2016-06-02 NZ NZ737796A patent/NZ737796A/en unknown
- 2016-06-02 PE PE2017002517A patent/PE20180317A1/es unknown
- 2016-06-02 CN CN202111063174.9A patent/CN114057872A/zh active Pending
- 2016-06-02 CA CA2986942A patent/CA2986942C/en active Active
- 2016-06-02 SG SG10201911349YA patent/SG10201911349YA/en unknown
- 2016-06-02 PL PL16728559.2T patent/PL3303386T3/pl unknown
- 2016-06-02 TW TW110121322A patent/TWI790642B/zh active
- 2016-06-02 AR ARP160101629A patent/AR104875A1/es unknown
- 2016-06-02 MA MA044955A patent/MA44955A/fr unknown
- 2016-06-02 TW TW111148795A patent/TWI827405B/zh active
- 2016-06-02 TW TW105117467A patent/TWI730963B/zh active
- 2016-06-02 UA UAA201713029A patent/UA126272C2/uk unknown
- 2016-06-02 CA CA3258972A patent/CA3258972A1/en active Pending
- 2016-06-02 IL IL314569A patent/IL314569A/en unknown
- 2016-06-02 US US15/171,143 patent/US10112990B2/en active Active
- 2016-06-02 IL IL300670A patent/IL300670B2/en unknown
- 2016-06-02 SI SI201631870T patent/SI3303386T1/sl unknown
- 2016-06-02 TW TW112144454A patent/TW202428606A/zh unknown
- 2016-06-02 FI FIEP16728559.2T patent/FI3303386T3/fi active
- 2016-06-02 DK DK16728559.2T patent/DK3303386T3/da active
- 2016-06-02 JP JP2017562681A patent/JP6793134B2/ja active Active
- 2016-06-02 MX MX2017015464A patent/MX392257B/es unknown
- 2016-06-02 PH PH1/2021/551770A patent/PH12021551770A1/en unknown
- 2016-06-02 CN CN201680033214.6A patent/CN107849124B/zh active Active
- 2016-06-02 AU AU2016270858A patent/AU2016270858B2/en active Active
-
2017
- 2017-11-09 IL IL255578A patent/IL255578B2/en unknown
- 2017-11-10 ZA ZA2017/07644A patent/ZA201707644B/en unknown
- 2017-11-28 PH PH12017502165A patent/PH12017502165A1/en unknown
- 2017-11-30 MX MX2022003272A patent/MX2022003272A/es unknown
- 2017-11-30 MX MX2022003273A patent/MX2022003273A/es unknown
- 2017-12-01 CL CL2017003063A patent/CL2017003063A1/es unknown
-
2018
- 2018-01-02 CO CONC2018/0000046A patent/CO2018000046A2/es unknown
- 2018-09-24 US US16/140,189 patent/US10329344B2/en active Active
- 2018-09-24 US US16/140,182 patent/US10336819B2/en active Active
-
2019
- 2019-05-07 US US16/405,359 patent/US10633436B2/en active Active
- 2019-10-25 ZA ZA2019/07054A patent/ZA201907054B/en unknown
- 2019-10-29 CL CL2019003114A patent/CL2019003114A1/es unknown
-
2020
- 2020-11-09 JP JP2020186282A patent/JP7403429B2/ja active Active
- 2020-12-03 US US17/110,969 patent/US11555065B2/en active Active
-
2021
- 2021-10-18 ZA ZA2021/07931A patent/ZA202107931B/en unknown
-
2022
- 2022-07-25 AU AU2022209213A patent/AU2022209213A1/en not_active Abandoned
- 2022-12-13 US US18/065,472 patent/US12486319B2/en active Active
-
2023
- 2023-08-18 JP JP2023133420A patent/JP7835706B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519810A5 (https=) | ||
| IL266911B1 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| FI3303386T3 (fi) | Tau-vasta-aineita ja käyttömenetelmiä | |
| JP2016503065A5 (https=) | ||
| JP2017536102A5 (https=) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2019528083A5 (https=) | ||
| JP2019527543A5 (https=) | ||
| JP2016526878A5 (https=) | ||
| JP2015533795A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| US20130108641A1 (en) | Anti-gitr antibodies | |
| JP2020509756A5 (https=) | ||
| JP2016539176A5 (https=) | ||
| JP2019522961A5 (https=) | ||
| JP2017534646A5 (https=) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2013519364A5 (https=) | ||
| JP2013538553A5 (https=) | ||
| JP2019527194A5 (https=) | ||
| JP2018503357A5 (https=) | ||
| JP2015501814A5 (https=) | ||
| JP2018505651A5 (https=) | ||
| JP2019521647A5 (https=) |